Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Settles Patent Dispute with Bioscientia Institute

NEW YORK (GenomeWeb News) – Genetic Technologies today announced it has settled a legal dispute with Bioscientia Institute for Medical Diagnostics and will withdraw its lawsuit against the German firm.

Melbourne, Australia-based GTG initiated legal action against Bioscientia in March related to GTG's non-coding technology. The company did not disclose details about the lawsuit, but GTG has sued numerous companies, alleging infringement of US Patent No. 5,612,179.

It has settled with several firms over its allegations, and today's announcement follows similar settlements announced in April with the Genetics & IVF Institute and PreventionGenetics.

Financial and other terms of today's deal were not disclosed.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.